Trials / Withdrawn
WithdrawnNCT01517308
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C, RELAPSERS TO PEG-IFN + RIBAVIRIN TREATMENT. A RANDOMIZED CONTROLLED TRIAL
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Federico II University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the efficacy of PEG-IFNα-2a + ribavirin administered for 24 or 48 weeks. It will be evaluated whether 48 weeks of therapy may achieve better results compared to the standard duration (24 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegylated interferon alpha 2a + ribavirin | Comparison of different duration of drugs (48 weeks vs. 24 weeks) |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2012-01-25
- Last updated
- 2012-03-19
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01517308. Inclusion in this directory is not an endorsement.